Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - SARS-CoV-2 and cancer 1

LBA76_PR - Expected medium and long term impact of the COVID-19 outbreak in oncology

Date

18 Sep 2020

Session

Mini Oral - SARS-CoV-2 and cancer 1

Presenters

Guy Jerusalem

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

G. Jerusalem1, C.E. Onesti2, D.G. Generali3, N. Harbeck4, H. Wildiers5, G. Curigliano6, M. Campone7, V. Tjan-Heijnen8, M. Martin9, M. Cristofanilli10, L. Pusztai11, R. Bartsch12, M. Peeters13, G. Berchem14, M. Tagliamento15, J. Cortés16, T. Ruhstaller17, E.M. Ciruelos18, S. Rottey19, H.S. Rugo20

Author affiliations

  • 1 Medical Oncology, CHU Sart Tilman Liège and University of Liège, 4000 - Liège/BE
  • 2 Medical Oncology, CHU Sart Tilman Liege and Laboratory of Human Genetics, GIGA Research Institute, University of Liège, 4000 - Liège/BE
  • 3 Uo Patologia Mammaria E Ricerca Traslazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, 26100 - Cremona/IT
  • 4 Breast Center, Dept. Ob&gyn And Cclmu, Ludwig Maximilians University Hospital, 81377 - Munich/DE
  • 5 Department Of General Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 6 Oncology And Hemato-oncology, European Institute of Oncology, IRCCS and University of Milan, 20141 - Milan/IT
  • 7 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 8 Medical Oncology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 9 Departamento De Medicina, Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense, 28009 - Madrid/ES
  • 10 Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 60611 - Chicago/US
  • 11 Yale Cancer Center, Yale School of Medicine, 06511 - New Haven/US
  • 12 Department Of Medicine 1,division Of Oncology, Comprehensive Cancer Center, Medical University of Vienna, 1090 - Vienna/AT
  • 13 Oncology Department, University Hospital Antwerp (UZA), 2650 - Edegem/BE
  • 14 Hemato-oncology Department, Centre Hospitalier de Luxembourg, 1210 - Luxembourg/LU
  • 15 Oncology Department, University of Genova and IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 16 Oncology Department, IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain & Vall d’Hebron Institute of Oncology (VHIO), 08023 - Barcelona/ES
  • 17 Med. Oncology, Breast Center of Eastern Switzerland, 9016 - St. Gallen/CH
  • 18 Medical Oncology, University Hospital 12 de Octubre, 28041 - Madrid/ES
  • 19 Department Of Medical Oncology, UZ Gent, 9000 - Gent/BE
  • 20 Breast Care Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 94158 - San Francisco/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA76_PR

Background

The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide.

Methods

A 95 items survey was distributed worldwide by 20 oncologists from 10 of the most affected countries in order to evaluate the impact on organization of oncological care.

Results

109 representatives from oncology centers in 18 countries (62.4% academic hospitals) filled out the survey (June 17 – July 14, 2020). A swab or gargle test is systematically performed before day care unit or overnight stay admissions in 27.5% and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing (77.1%) of infected patients was organized in many centers. Treatment modalities mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in 32.1% of centers, and 64.2 % of participants agree that under-treatment is a major concern. At the pandemic peak, teleconsultations were performed for follow-up (94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy (57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that they will continue to use telemedicine. Most participants reported more frequent use of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree that virtual meetings are an acceptable alternative to live international meetings. Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4% had an increased scientific activity. Only 18% of participants estimate that their well-being will not recover to previous levels by the end of the year; 63% indicate easily accessible psychological support for caregivers, but only 10% used or planned to use it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers. Major study protocol violations/deviations were observed in 27.5% and significant reductions of clinical trial activities are expected by 37% of centers this year.

Conclusions

COVID-19 has a major impact on organization of patient care, well-being of caregivers, continued medical education and clinical trial activities in oncology.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Fondation Léon Fredericq.

Disclosure

G. Jerusalem: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: AbbVie; Travel/Accommodation/Expenses: MedImmune; Travel/Accommodation/Expenses: Merck KGaA. G. Curigliano: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Speaker Bureau/Expert testimony, Writing engagement: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy, Speaker Bureau/Expert testimony: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celltrion; Leadership role, Scientific Affairs Group: Ellipsis; Speaker Bureau/Expert testimony, Writing engagement: BMS; Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan. M. Campone: Honoraria (self), Advisory/Consultancy: GT1; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: Pierre-Favre; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Servier; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy: Accord; Honoraria (institution), Advisory/Consultancy: Pfizer; Speaker Bureau/Expert testimony: Lilly. M. Martin: Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Puma; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Amgen; Advisory/Consultancy: Taiho Oncology; Advisory/Consultancy: Daichii Sankyo; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Pfizer. M. Cristofanilli: Advisory/Consultancy: CytoDyn; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy: G1 Therapeutics; Advisory/Consultancy: Sermionexx; Advisory/Consultancy: Genentch. L. Pusztai: Honoraria (self), Research grant/Funding (institution), Clinical trial support: Merck; Honoraria (self), Research grant/Funding (institution), Clinical trial support: AstraZeneca; Honoraria (self), Research grant/Funding (institution), Clinical trial support: Seattle Genetics; Honoraria (self): Novartis; Honoraria (self), Research grant/Funding (institution), Clinical trial support: Roche Genentech; Honoraria (self): Eisai; Honoraria (self): Daiichi; Honoraria (self): Syndax; Honoraria (self): Immunomedics. R. Bartsch: Advisory/Consultancy: Accord; Honoraria (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Daiichi; Advisory/Consultancy, Travel/Accommodation/Expenses: Eli-Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Puma; Advisory/Consultancy: Pierre-Favre; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Eisai. M. Tagliamento: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Amgen. J. Cortés: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Celgene; Advisory/Consultancy: Cellestia; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biothera Pharmaceutical; Advisory/Consultancy: Merus; Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Erytech; Advisory/Consultancy: Athenex + Polyphor; Advisory/Consultancy, Shareholder/Stockholder/Stock options: MedSIR; Honoraria (self), Advisory/Consultancy: Lilly; Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp Dome; Advisory/Consultancy: GSK; Advisory/Consultancy: Leuko; Advisory/Consultancy: Bioasis; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: Eisai; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Samsung Bioepis; Research grant/Funding (institution): Ariad Pharmaceuticals; Research grant/Funding (institution): Baxalta GMBH/Servier Affaires; Research grant/Funding (institution): Bayer Healthcare; Research grant/Funding (institution): F. Hoffmann-La Roche; Research grant/Funding (institution): Guardanth Health; Research grant/Funding (institution): Piqur THerapeutics; Research grant/Funding (institution): Puma C; Research grant/Funding (institution): Queen Mary University of London. E.M. Ciruelos: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer. H.S. Rugo: Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly; Research grant/Funding (institution), Travel/Accommodation/Expenses: MacroGenics; Research grant/Funding (institution): Merck; Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Obi Pharma; Research grant/Funding (institution): Odonate Therapeutics; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Daiichi-Sankyo; Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Samsung; Advisory/Consultancy: Celtrion; Travel/Accommodation/Expenses: Mylan; Travel/Accommodation/Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings